The following represents disclosure information provided by authors of this abstract. ASCO's Quality Care Symposium Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Assessment of single-institution HER2 testing patterns, rate of HER2+ disease, and utilization of trastuzumab in early breast cancer.
David D. Stenehjem
Research Funding - Genentech
Minkyoung Yoo
No relevant relationships to disclose
Sudhir K. Unni
No relevant relationships to disclose
Mukul Singhal
No relevant relationships to disclose
Hillevi Bauer
No relevant relationships to disclose
Kim Saverno
No relevant relationships to disclose
Cheng Seok Quah
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Genentech/Roche
Anthony Masaquel
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Genentech/Roche
Research Funding - Genentech/Roche
Diana I. Brixner
Research Funding - Genentech